Clexio Biosciences
Tel Aviv, Israel· Est.
Israeli biotech developing NMDA‑antagonist and KV7‑channel therapies for depression and epilepsy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli biotech developing NMDA‑antagonist and KV7‑channel therapies for depression and epilepsy.
Major Depressive DisorderEpilepsy
Technology Platform
Selective NMDA receptor antagonism (CLE‑100) and KV7.2/3 potassium channel activation (CLE‑043) as oral small‑molecule therapies for neuropsychiatric disorders.
Opportunities
Large unmet need in treatment‑resistant depression and refractory epilepsy, with potential for oral, fast‑acting therapies and partnership or licensing opportunities.
Risk Factors
Clinical failure risk in Phase 2, competition from other NMDA modulators and KV7 channel agents, and reliance on future financing to advance pipeline.
Competitive Landscape
Competes with NMDA‑targeting antidepressants (e.g., esketamine) and emerging KV7 channel openers; differentiation hinges on oral delivery, safety profile, and dual‑indication strategy.